Jamie M. Jacobs|Nicole Pensak|Nora Sporn|James MacDonald|Inga T. Lennes|Steven A. Safren|William F. Pirl|Jennifer S. Temel|Joseph A. Greer
Treatment Satisfaction and Adherence to Oral Chemotherapy in Patients With Cancer
University of Miami|University of Colorado Denver|Boston University|Harvard University|University of California, Los Angeles|University of Miami|University of Colorado Denver|Boston University|Harvard University|University of California, Los Angeles|University of Miami|University of Colorado Denver|Boston University|Harvard University|University of California, Los Angeles|University of Miami|University of Colorado Denver|Boston University|Harvard University|University of California, Los Angeles|University of Miami|University of Colorado Denver|Boston University|Harvard University|University of California, Los Angeles|University of Miami|University of Colorado Denver|Boston University|Harvard University|University of California, Los Angeles|University of Miami|University of Colorado Denver|Boston University|Harvard University|University of California, Los Angeles|University of Miami|University of Colorado Denver|Boston University|Harvard University|University of California, Los Angeles|University of Miami|University of Colorado Denver|Boston University|Harvard University|University of California, Los Angeles
although patients cancer overwhelming prefer oral intravenous chemotherapy little known adherence oral agents aimed identify rates correlates adherence patients diverse malignanciesninety patients chronic myeloid leukemia metastatic renal cell carcinoma nonsmallcell lung cancer breast cancer enrolled prospective singlegroup observational study medicationtaking behaviors adherence measured via selfreport electronic pill cap medication event monitoring system cap patients completed surveys regarding symptom distress mood quality life cancerspecific distress satisfaction clinician communication treatment baseline 12week followupas measured medication event monitoring system patients took average 893 prescribed oral chemotherapy 12 weeks one quarter sample less 90 adherent women adherent men mean difference 959 se difference 450 95 ci 1865 052 p 039 improvements patient symptom distress b 079 95 ci 141 018 depressive symptoms b 157 95 ci 286 029 quality life b 038 95 ci 007 068 satisfaction clinician communication treatment b 073 95 ci 049 098 perceived burden others b 128 95 ci 220 037 associated better adherence multivariate model improved treatment satisfaction b 071 95 ci 048 094 reduced perceived burden b 092 95 ci 176 009 strongest indicators better adherencewomen patients reported increased treatment satisfaction reduced burden others adherent oral chemotherapy interventions help patients improve communication clinicians reduce burden may optimize oral chemotherapy adherence